Mathilde Gay-Bellile

Mathilde Gay-Bellile

Auto-generated profile, based on publicly available information

Mathilde Gay-Bellile

Département d’Oncogénétique, Centre Jean Perrin, 63011 Clermont-Ferrand, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2017 in Oncotarget
Verified
Journal Article
Open access
MGMathilde Gay-Bellile
Mathilde Gay-Bellile
LVLauren Véronèse
Lauren Véronèse
PCPatricia Combes
Patricia Combes
EEEleonore Eymard-Pierre
Eleonore Eymard-Pierre
FKFabrice Kwiatkowski
Fabrice Kwiatkowski
ATAndrei Tchirkov
Andrei Tchirkov
TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer

17 July 2013 in European Journal of Human Genetics
Verified
Journal Article
Closed access
CPCéline Pebrel-Richard
Céline Pebrel-Richard
ADAnne Debost-Legrand
Anne Debost-Legrand
EEEléonore Eymard-Pierre
Eléonore Eymard-Pierre
VGVictoria Greze
Victoria Greze
SKStéphan Kemeny
Stéphan Kemeny
CFChristine Francannet
Christine Francannet

25 November 2014 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
CGCarole Goumy
Carole Goumy
FLFanny Laffargue
Fanny Laffargue
EEEléonore Eymard‐Pierre
Eléonore Eymard‐Pierre
SKStéphen Kemeny
Stéphen Kemeny
MGMathilde Gay‐Bellile
Mathilde Gay‐Bellile
PVPhilippe Vago
Philippe Vago

29 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
RGRomain Guièze
Romain Guièze
MPMélanie Pages
Mélanie Pages
LVLauren Véronèse
Lauren Véronèse
PCPatricia Combes
Patricia Combes
RLRichard Lemal
Richard Lemal
ATAndrei Tchirkov
Andrei Tchirkov
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Romain Guièze1, *, Mélanie Pages2, *, Lauren Véronèse3, Patricia Combes3, Richard Lemal1, Mathilde Gay-bellile3, Martine Chauvet4, Mary Callanan4, Fabrice Kwiatkowski5, Bruno Pereira6, Philippe Vago3, Jacques-Olivier Bay1, Olivier Tournilhac1, Andreï Tchirkov3 1CHU Clermont-Ferrand, Hématologie Clinique, Clermont-Ferrand, F-63003; EA 7283 CREaT, Université d’Auvergne Clermont-Ferrand, France 2Department de Neuropathologie, Hôpital Sainte-Anne, Paris, France; Université Paris Descartes, Paris, France 3Univ Clermont 1, UFR Médecine, Cytologie Histologie Embryologie Cytogénétique, Clermont-Ferrand, F-63001; CHU Clermont-Ferrand, Cytogénétique Médicale, Clermont-Ferrand, F-63003; EA 4677 ERTICa, Université d’Auvergne, Clermont-Ferrand, France 4Inserm U823, Institut Albert Bonniot & Université Joseph Fourier, Grenoble, France; CHU Grenoble, Laboratoire de Génétique Onco-hématologique, Grenoble, France 5Centre Jean Perrin, Clermont-Ferrand, France; EA 4677 ERTICa, Université d’Auvergne, Clermont-Ferrand, France 6Direction de la Recherche Clinique et de l’Innovation, Département de Biostatistiques, CHU Clermont-Ferrand, Clermont-Ferrand, France *These authors have contributed equally to this work Correspondence to: Andreï Tchirkov, email: atchirkov@chu-clermontferrand.fr Keywords: chronic lymphocytic leukemia, TP53, telomere, hTERT, shelterin Received: April 13, 2016 Accepted: July 10, 2016 Published: July 29, 2016

31 May 2016 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
MGMathilde Gay‐Bellile
Mathilde Gay‐Bellile
PRPierre Romero
Pierre Romero
ACAnne Cayre
Anne Cayre
LVLauren Véronèse
Lauren Véronèse
MPMaud Privat
Maud Privat
ATAndrei Tchirkov
Andrei Tchirkov
Dysfunctional telomeres and DNA damage repair (DDR) play important roles in cancer progression. Studies have reported correlations between these factors and tumour aggressiveness and clinical outcome in breast cancer. We studied the characteristics of telomeres and expression of ERCC1, a protein involved in a number of DNA repair pathways and in telomere homeostasis, to assess their prognostic value, alone or in combination, in 90 residual breast tumours after treatment with neoadjuvant chemotherapy (NCT). ERCC1 status was investigated at different molecular levels (protein and gene expression and gene copy‐number variations) by immunohistochemistry, qRT‐PCR and quantitative multiplex fluorescent‐PCR (QMF‐PCR). A comprehensive analysis of telomere characteristics was performed using qPCR for telomere length and qRT‐PCR for telomerase (hTERT), tankyrase 1 (TNKS) and shelterin complex (TRF1, TRF2, POT1, TPP1, RAP1 and TIN2) gene expression. Short telomeres, high hTERT and TNKS expression and low ERCC1 protein expression were independently associated with worse survival outcome. Interestingly, ERCC1 gains and losses correlated with worse disease‐free (p = 0.026) and overall (p = 0.043) survival as compared to survival of patients with normal gene copy‐numbers. Unsupervised hierarchical clustering of all ERCC1 and telomere parameters identified four subgroups with distinct prognosis. In particular, a cluster combining low ERCC1, ERCC1 gene alterations, dysfunctional telomeres and high hTERT and a cluster with high TNKS and shelterin expression correlated with poor disease‐free (HR= 5.41, p= 0.0044) and overall survival (HR= 6.01, p= 0.0023) irrespective of tumour stage and grade. This comprehensive study demonstrates that telomere dysfunction and DDR can contribute synergistically to tumour progression and chemoresistance. These parameters are predictors of clinical outcome in breast cancer patients treated with NCT and could be useful clinically as prognostic biomarkers to tailor adjuvant chemotherapy post‐NCT.

31 August 2018 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
MCMathias Cavaillé
Mathias Cavaillé
FPFlora Ponelle-Chachuat
Flora Ponelle-Chachuat
NUNancy Uhrhammer
Nancy Uhrhammer
SVSandrine Viala
Sandrine Viala
MGMathilde Gay-Bellile
Mathilde Gay-Bellile
BYBIGNON Yves-Jean
BIGNON Yves-Jean
A family with an aggregation of rare early onset multiple primary tumors has been managed in our oncogenetics department: the proband developed four early onset carcinomas between ages 31 and 33 years, including acral melanoma, bilateral clear cell renal carcinoma (RC), and follicular variant of papillary thyroid carcinoma. The proband’s parent developed orbital lymphoma and small intestine mucosa-associated lymphoid tissue (MALT) lymphoma between 40 and 50 years old. Whole-exome-sequencing (WES) of the nuclear family (proband, parents, and sibling) identified in the proband a de novo deleterious heterozygous mutation c.1003C > T (p.Arg335∗) in the phosphatase and tensin homolog (PTEN) gene. Furthermore, WES allowed analysis of the nuclear family’s genetic background, and identified deleterious variants in two candidate modifier genes: CEACAM1 and MIB2. CEACAM1, a tumor suppressor gene, presents loss of expression in clear cell RC and is involved in proliferation of B cells. It could explain in part the phenotype of proband’s parent and the occurrence of clear cell RC in the proband. Deleterious mutations in the MIB2 gene are associated with melanoma invasion, and could explain the occurrence of melanoma in the proband. Cowden syndrome is a hereditary autosomal dominant disorder associated with increased risk of muco-cutaneous features, hamartomatous tumors, and cancer. This atypical presentation, including absence of muco-cutaneous lesions, four primary early onset tumors and bilateral clear cell RC, has not been described before. This encourages including the PTEN gene in panel testing in the context of early onset RC, whatever the histological subtype. Further studies are required to determine the implication of CEACAM1 and MIB2 in the severity of Cowden syndrome in our proband and occurrence of early onset MALT lymphoma in a parent.